The results of the SAVE trial 45 will be particularly relevant to the present findings.
The SAVE trial (Super-dose Anti- VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for Recalcitrant Neovascular Age-Related Macular Degeneration) demonstrated significant visual and anatomic gains in recalcitrant wet AMD eyes at both 1 and 2 years of treatment.
In the Survival And Ventricular Enlargement (SAVE) trial, post-myocardial randomization to captopril resulted in a reduction of cardiovascular events, regardless of renal function [ 38].
Machold KP, Landewé R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
To assess the effects of weight loss and decreased fasting insulin on vascular stiffness, we studied 339 participants in the Slow the Adverse Effects of Vascular Aging (SAVE) trial.
The SAVE trial focuses on this segment of the population enabling the study of the effects of obesity and the early stages of insulin resistance prior to the onset of diabetes.
Inclusion criteria were that only patients who completed the 2-year, prospective SAVE trial (NCT01025232) in which recalcitrant wet AMD eyes were treated with 2.0 mg ranibizumab 7 9 were eligible.
8 The current study aimed to determine if 2.0 mg aflibercept could maintain or even improve upon the visual acuity and anatomic gains of the SAVE trial for these well-characterised recalcitrant exudative AMD eyes.
That $10 million retains its character as ordinary income, but because it is treated as a shareholder distribution rather than wage or self-employment income, the distribution avoids the Medicare tax, and saves the trial lawyer nearly $290,000 in tax liability.
Nevertheless, in some cases raising the sample size will make sense, and may save the trial from unnecessary disaster.
